Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

Related Articles by Review for PubMed (Select 20518712)

1.

Gene-expression profiling in vaccine therapy and immunotherapy for cancer.

Bedognetti D, Wang E, Sertoli MR, Marincola FM.

Expert Rev Vaccines. 2010 Jun;9(6):555-65. doi: 10.1586/erv.10.55. Review.

2.

Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.

Mocellin S, Rossi CR, Nitti D, Lise M, Marincola FM.

Biochim Biophys Acta. 2003 Dec 5;1653(2):61-71. Review.

PMID:
14643925
3.

Antitumor vaccines, immunotherapy and the immunological constant of rejection.

Wang E, Monaco A, Monsurró V, Sabatino M, Pos Z, Uccellini L, Wang J, Worschech A, Stroncek DF, Marincola FM.

IDrugs. 2009 May;12(5):297-301. Review.

4.

Progress in human tumour immunology and immunotherapy.

Rosenberg SA.

Nature. 2001 May 17;411(6835):380-4. Review.

PMID:
11357146
5.

Therapeutic gene modified cell based cancer vaccines.

Kozłowska A, Mackiewicz J, Mackiewicz A.

Gene. 2013 Aug 10;525(2):200-7. doi: 10.1016/j.gene.2013.03.056. Epub 2013 Apr 6. Review.

PMID:
23566846
6.

T cell-mediated immune responses in melanoma: implications for immunotherapy.

Wang RF, Zeng G, Johnston SF, Voo K, Ying H.

Crit Rev Oncol Hematol. 2002 Jul;43(1):1-11. Review.

PMID:
12098604
7.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

8.

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.

Knutson KL, Disis ML.

Clin Breast Cancer. 2001 Apr;2(1):73-9. Review.

PMID:
11899386
9.

Next generation of immunotherapy for melanoma.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ.

J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423. Review.

PMID:
18612161
10.

The future of interleukin-2: enhancing therapeutic anticancer vaccines.

Overwijk WW, Theoret MR, Restifo NP.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S76-80. Review.

11.
12.

T-cell-directed cancer vaccines: the melanoma model.

Wang E, Phan GQ, Marincola FM.

Expert Opin Biol Ther. 2001 Mar;1(2):277-90. Review.

PMID:
11727535
13.

Therapeutic cancer vaccines: using unique antigens.

Lewis JJ.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14653-6. Epub 2004 Aug 5. Review.

14.

Human tumor antigens for cancer vaccine development.

Wang RF, Rosenberg SA.

Immunol Rev. 1999 Aug;170:85-100. Review.

PMID:
10566144
15.

Cellular vaccine approaches.

Le DT, Pardoll DM, Jaffee EM.

Cancer J. 2010 Jul-Aug;16(4):304-10. doi: 10.1097/PPO.0b013e3181eb33d7. Review.

16.

Targeting the immune system in cancer.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK.

Curr Pharm Biotechnol. 2009 Feb;10(2):166-84. Review.

PMID:
19199949
17.

Active-specific immunization against melanoma: is the problem at the receiving end?

Monsurrò V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM.

Semin Cancer Biol. 2003 Dec;13(6):473-80. Review.

PMID:
15001166
18.

Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield?

Mocellin S, Panelli M, Wang E, Rossi CR, Marincola FM.

Tumori. 2002 Nov-Dec;88(6):437-44. Review.

PMID:
12597134
19.

[Vaccine strategies against melanoma].

Ghiringhelli F, Zitvogel L.

Med Sci (Paris). 2006 Feb;22(2):183-7. Review. French.

20.

Regulation of tumor progression by anti-neoplastic T cell responses.

Abrams SI.

Cancer Biol Ther. 2004 Feb;3(2):140-6. Epub 2004 Feb 1. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk